Femtogenix was founded in 2015 to discover and develop next generation DNA-interactive payload molecules for use in antibody-drug conjugates. Our payloads are designed through a development platform combining proprietary computational chemistry techniques, and founder know-how gained from a combined 50+ years of experience in DNA-targeted drug discovery and development.
Our drug discovery platform allows us to design molecules capable of binding reversibly and/or irreversibly to DNA, in a sequence-interactive manner, leading to exquisite cytotoxicity toward tumour cells. When attached to antibodies or other targeting moieties, these potent cytototoxic agents can be delivered directly to tumours with minimal general systemic toxicities for patients.
Our management and scientific teams consist of highly experienced scientists with the expertise and drive to translate our novel platform into tangible results for cancer patients.